Evogene (EVGN) Interest & Investment Income (2013 - 2026)
Evogene (EVGN) posted Interest & Investment Income of $1.2 million for Q1 2026, up 546.96% sequentially from $181000.0 in Q4 2025, and down 26.07% YoY from $1.6 million in Q1 2025.
Evogene (EVGN) Interest & Investment Income (2013 - 2026) Analysis & Trends
Evogene has reported Interest & Investment Income for 14 years, with the latest figure at $1.2 million in Q1 2026.
- Quarterly Interest & Investment Income fell 26.07% year-over-year to $1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.1 million (down 76.08% YoY) and the FY2025 annual result came in at $2.5 million, down 66.08% from the prior year.
- Interest & Investment Income advanced to $1.2 million in Q1 2026 per EVGN's latest filing, from $181000.0 in the prior quarter.
- Over five years, Interest & Investment Income peaked at $4.7 million in Q4 2024 and troughed at $41000.0 in Q1 2022.
- A 5-year average of $786647.1 and a median of $391000.0 in 2023 frame the typical range for Interest & Investment Income.
- The sharpest annual moves came in 2024 and 2025: Interest & Investment Income soared 1222.35% in 2024, then slumped 96.18% in 2025.
- Over 5 years, Interest & Investment Income stood at $169000.0 in 2022, then surged by 111.83% to $358000.0 in 2023, then jumped by 1222.35% to $4.7 million in 2024, then plunged by 96.18% to $181000.0 in 2025, then surged by 546.96% to $1.2 million in 2026.
- According to Business Quant data, Interest & Investment Income over the past three periods registered $1.2 million, $181000.0, and $465000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | Evogene | 4.38 Mn | 4.38 Mn | 204,000.00 | 1.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.17 Mn |
| Dec 31, 2025 | 181,000.00 |
| Sep 30, 2025 | 465,000.00 |
| Jun 30, 2025 | 235,000.00 |
| Mar 31, 2025 | 1.58 Mn |
| Dec 31, 2024 | 4.73 Mn |
| Sep 30, 2024 | 2.07 Mn |
| Jun 30, 2024 | 194,000.00 |
| Mar 31, 2024 | 407,000.00 |
| Dec 31, 2023 | 358,000.00 |
| Sep 30, 2023 | 429,000.00 |
| Jun 30, 2023 | 391,000.00 |
| Mar 31, 2023 | 308,000.00 |
| Dec 31, 2022 | 169,000.00 |
| Sep 30, 2022 | 194,000.00 |
| Jun 30, 2022 | 444,000.00 |
| Mar 31, 2022 | 41,000.00 |
| Dec 31, 2021 | 938,000.00 |
| Sep 30, 2021 | 380,000.00 |
| Jun 30, 2021 | 565,000.00 |